The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors

被引：0
|
作者：
Vladimer Darsalia
Martin Larsson
Thomas Klein
Cesare Patrone
机构：
[1] Karolinska Institutet,Department of Clinical Science and Education, Södersjukhuset, Internal Medicine
[2] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
来源：
Cardiovascular Diabetology | / 17卷
关键词：
Glucagon-like peptide 1 receptor; Dipeptidyl peptidase-4 inhibitors; Stroke; Diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors
    Egan, Aoife M.
    Montori, Victor M.
    ANNALS OF INTERNAL MEDICINE, 2018, 169 (02) : JC2 - JC2
  • [42] GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
    Gilbert, Matthew P.
    Pratley, Richard E.
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [43] Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
    Mann, Johannes F. E.
    Muskiet, Marcel H. A.
    KIDNEY INTERNATIONAL, 2021, 99 (02) : 314 - 318
  • [44] The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study
    Al-Mashhadi, Zheer Kejlberg
    Viggers, Rikke
    Fuglsang-Nielsen, Rasmus
    Vestergaard, Peter
    Gregersen, Soren
    Starup-Linde, Jakob
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [45] The pharmacological basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors (vol 123, pg 189, 2011)
    Morales, J.
    POSTGRADUATE MEDICINE, 2012, 124 (01) : 177 - 178
  • [46] The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway
    Fausto Chiazza
    Harald Tammen
    Hiranya Pintana
    Grazyna Lietzau
    Massimo Collino
    Thomas Nyström
    Thomas Klein
    Vladimer Darsalia
    Cesare Patrone
    Cardiovascular Diabetology, 17
  • [47] The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway
    Chiazza, Fausto
    Tammen, Harald
    Pintana, Hiranya
    Lietzau, Grazyna
    Collino, Massimo
    Nystrom, Thomas
    Klein, Thomas
    Darsalia, Vladimer
    Patrone, Cesare
    CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [48] Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)
    Charalampos I. Liakos
    Dimitrios P. Papadopoulos
    Elias A. Sanidas
    Maria I. Markou
    Erifili E. Hatziagelaki
    Charalampos A. Grassos
    Maria L. Velliou
    John D. Barbetseas
    American Journal of Cardiovascular Drugs, 2021, 21 : 123 - 137
  • [49] Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)
    Liakos, Charalampos I.
    Papadopoulos, Dimitrios P.
    Sanidas, Elias A.
    Markou, Maria I.
    Hatziagelaki, Erifili E.
    Grassos, Charalampos A.
    Velliou, Maria L.
    Barbetseas, John D.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2021, 21 (02) : 123 - 137
  • [50] Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors
    Boland, Cassie L.
    DeGeeter, Michelle
    Nuzum, Donald S.
    Tzefos, Maria
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (04) : 490 - 505
12345